Determining the extent of tumor resection at surgical planning with F-fluciclovine PET/CT in patients with suspected glioma: multicenter phase III trials.

Objective: Glioma is the most common type of central nervous system tumor reported worldwide. Current imaging technologies have limitations in the diagnosis and assessment of glioma. The present study aimed to confirm the diagnostic efficacy and safety of anti-1-amino-3-[F]fluorocyclobutane carboxylic acid (F-fluciclovine; anti-[F]FACBC) as a radiotracer for patients undergoing combined positron emission tomography and computed tomography (PET/CT) for suspected glioma.

Diagnostic Performance and Safety of Positron Emission Tomography Using F-Fluciclovine in Patients with Clinically Suspected High- or Low-grade Gliomas: A Multicenter Phase IIb Trial.

Objectives: The study objective was to assess the diagnostic performance of positron emission tomography (PET) for gliomas using the novel tracer F-fluciclovine (anti-[F]FACBC) and to evaluate the safety of this tracer in patients with clinically suspected gliomas.

Methods: Anti-[F]FACBC was administered to 40 patients with clinically suspected high- or low-grade gliomas, followed by PET imaging. T1-weighted, contrast-enhanced T1-weighted, and fluid-attenuated inversion recovery (or T2-weighted) magnetic resonance imaging (MRI) scans were obtained to plan for the tissue collection.